Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Prognostic value of minimal residual disease detection by circulating tumor DNA in Hodgkin lymphoma.

View Full Paper
Ask AI
Bookmark
Share

Authors

AGAna García‐BacelarMPMaría Jesús Peñarrubia PonceABAna Balanzategui-Echevarría

Discussion

Loading...

Member takes

Overview

Observational analysis reveals prognostic impact of ctDNA and PET/CT on survival in Hodgkin lymphoma.

Key Points

  • MRD detected by circulating tumor DNA improves prognostic stratification in Hodgkin lymphoma patients.
  • At 3 years, patients with MRD(–) had a progression-free survival of 88% compared to 25% for MRD(+).
  • Analysis using Next Generation Sequencing on peripheral blood samples was conducted post-treatment to evaluate tumor status.
  • Combining PET/CT and MRD assessment identifies distinct prognostic groups with varying survival outcomes.

Cite This Study

García‐Bacelar et al. (2025) studied this question.

synapsesocial.com/papers/69362f714fa91c937236e22dhttps://doi.org/10.1182/blood-2025-3541
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Integration of longitudinal ctdna MRD and PET/CT enhances prognostic stratification in newly diagnosed diffuse large B-cell lymphoma: A prospective multicenter study2025
  2. 2Remission Assessment by Circulating Tumor DNA in Large B-cell Lymphoma2025 · 31 citations
  3. 3Circulating tumor DNA-based minimal residual disease assessment predicts progression-free survival in diffuse large B-cell lymphoma: A systematic review and meta-analysis2025 · 1 citations
  4. 4Precise-HL trial: Personalized reduction of chemotherapy intensity through ctdna evaluation in advanced Hodgkin lymphoma2025 · 3 citations
  5. 5Monitoring ctDNA in Aggressive B-cell Lymphoma: A Prospective Correlative Study of ctDNA Kinetics and PET-CT Metrics2025 · 4 citations